MOLECULAR PROFILING IN LOW-GRADE EC 71 3 eTable 2. Baseline characteristics of the included versus excluded patients Included N=393 Excluded N=296 P Patient characteristic Age (years) 63.0 (31.0-82.0) 64.5 (35.0-93.0) .09 Pathologic characteristics POLE-mutant 33 (8.4) 14 (4.7) .001 MSI 78 (19.8) 79 (26.7) TP53-mutant 72 (18.3) 29 (9.8) NSMP 210 (53.4) 174 (58.8) Histology EEC 318 (80.9) 275 (92.9) <.001 NEEC 75 (19.1) 21 (7.1) Grade 1-2 209 (53.2) 217 (73.3) <.001 3 184 (46.8) 79 (26.7) MI <50% 197 (50.1) 178 (61.0) .006 >50% 194 (49.4) 114 (39.0) Unknown 2 (0.5) LVSI No 304 (77.4) 238 (80.4) .33 Yes 89 (22.6) 58 (19.6) Adjuvant treatment None 97 (24.7) 148 (50.3) <.001 Radiotherapy 225 (57.3) 124 (42.2) Chemotherapy 33 (8.4) 17 (5.8) Chemoradiation 34 (8.7) 5 (1.7) Unknown 4 (1.0) Mortality Recurrence 74 (18.8) 38 (12.8) .013 Mortality 90 (22.9) 55 (18.6) .17 EC-related mortality 73 (18.6) 26 (8.8) <.001 Data is presented as No. (%), median (IQR) Abbreviations: POLE, Polymerase epsilon; MSI, Microsatellite instability; TP53, Tumor protein 53; NSMP, Nospecific molecular profile; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial cancer; MI, myometrial invasion; LVSI, lymphovascular space invasion; EC, endometrial cancer.
RkJQdWJsaXNoZXIy MTk4NDMw